US FDA appeals against court ruling that Myblu can remain on sale pending review

The US Food and Drug Administration (FDA) has hit back at a court-issued stay allowing Fontem’s Myblu vaping products to continue to be legally sold in the US.

The agency has argued that the Tobacco Control Act makes Fontem’s products unlawful to be sold without market authorisation. It says all a court can do is return a marketing denial order (MDO) to the FDA for review and that while that review is taking place, products cannot be legally sold.

Read full article
I'm already a subscriber
Author default picture


This article was written by one of ECigIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual vaping markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global e-cigarette market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

ECigIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization